Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Gyre Therapeutics Inc. (GYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.39% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 600.06M USD | Price to earnings Ratio 128.2 | 1Y Target Price 20 |
Price to earnings Ratio 128.2 | 1Y Target Price 20 | ||
Volume (30-day avg) 183149 | Beta - | 52 Weeks Range 6.17 - 19.00 | Updated Date 04/2/2025 |
52 Weeks Range 6.17 - 19.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate 0.04 | Actual -0.0011 |
Profitability
Profit Margin 11.43% | Operating Margin (TTM) 2.38% |
Management Effectiveness
Return on Assets (TTM) 8.39% | Return on Equity (TTM) 20.24% |
Valuation
Trailing PE 128.2 | Forward PE - | Enterprise Value 574982753 | Price to Sales(TTM) 5.67 |
Enterprise Value 574982753 | Price to Sales(TTM) 5.67 | ||
Enterprise Value to Revenue 5.44 | Enterprise Value to EBITDA 32.27 | Shares Outstanding 93612400 | Shares Floating 23939510 |
Shares Outstanding 93612400 | Shares Floating 23939510 | ||
Percent Insiders 80.84 | Percent Institutions 2.12 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Gyre Therapeutics Inc.
Company Overview
History and Background
Gyre Therapeutics, Inc. (GYRE) is a biopharmaceutical company focused on developing innovative therapies for inflammatory and fibrotic diseases. It was formerly known as Leading BioSciences, Inc., and changed its name in July 2023. They've pivoted from prior indications to focus on KLK1 inhibitors.
Core Business Areas
- Drug Development: Focuses on researching and developing novel therapies for inflammatory and fibrotic diseases.
- KLK1 Inhibitors: Developing inhibitors targeting KLK1 to treat diseases with an inflammatory component.
Leadership and Structure
The leadership team includes experienced professionals in drug development and biotechnology. Details about the full organizational structure are generally proprietary.
Top Products and Market Share
Key Offerings
- Cerenodia: Cerenodia (formerly LB1148) is an investigational therapy being developed for treatment of certain inflammatory conditions. It has not received market approval. Currently in clinical trials. Competitors include existing therapies for inflammatory diseases, which have different mechanisms of action.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and characterized by rapid technological advancements and stringent regulatory requirements. It is also affected by the economy and the cost to bring drugs to market.
Positioning
Gyre Therapeutics focuses on developing innovative therapies for underserved patient populations. Their competitive advantage lies in the novelty of their therapeutic targets (KLK1 inhibition).
Total Addressable Market (TAM)
TAM depends on the specific indication Cerenodia targets. For example, inflammatory bowel disease (IBD) market is projected to be multi-billion USD. GYRE is positioned to capture a portion of this TAM if Cerenodia proves safe and effective.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (KLK1)
- Experienced leadership team
- Potential for breakthrough therapy designation
Weaknesses
- Limited financial resources
- Reliance on a single drug candidate
- Clinical trial risks and uncertainties
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Funding constraints
Competitors and Market Share
Key Competitors
Competitive Landscape
Gyre Therapeutics competes with established pharmaceutical companies and other biotech firms developing therapies for inflammatory and fibrotic diseases. Their KLK1 inhibition approach provides a potential differentiator, but they lack the resources of larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage.
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential partnerships.
Recent Initiatives: Focus on development of Cerenodia and securing funding for trials.
Summary
Gyre Therapeutics is a speculative early-stage biotech firm targeting a novel pathway. Its future success hinges on the positive results of clinical trials and its ability to secure funding. There are significant risks associated with the company, primarily due to the high failure rate of drug development. However, success can result in large returns.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- News sources
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The pharmaceutical industry is a risky field and should be treated as such.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gyre Therapeutics Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2006-04-12 | CEO & Director Dr. Han Ying Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 579 | Website https://www.gyretx.com |
Full time employees 579 | Website https://www.gyretx.com | ||
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.